Sigyn Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Sigyn Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2016 to Q3 2024.
  • Sigyn Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -109 %, a 5.84% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -109 +6.77 +5.84% Sep 30, 2024
Q2 2024 -109 +9.8 +8.24% Jun 30, 2024
Q1 2024 -110 +14.5 +11.6% Mar 31, 2024
Q4 2023 -114 +13.7 +10.7% Dec 31, 2023
Q3 2023 -116 +32.8 +22% Sep 30, 2023
Q2 2023 -119 +145 +55% Jun 30, 2023
Q1 2023 -124 -1.38K -110% Mar 31, 2023
Q4 2022 -128 -507 -134% Dec 31, 2022
Q3 2022 -149 -399 -160% Sep 30, 2022
Q2 2022 -264 -851 -145% Jun 30, 2022
Q1 2022 1.25K +2.13K Mar 31, 2022
Q4 2021 380 +1.99K Dec 31, 2021
Q3 2021 250 +1.49K Sep 30, 2021
Q2 2021 586 +862 Jun 30, 2021
Q1 2021 -872 -709 -435% Mar 31, 2021
Q4 2020 -1.61K -1.49K Dec 31, 2020
Q3 2020 -1.24K -1.12K -920% Sep 30, 2020
Q2 2020 -276 -144 -110% Jun 30, 2020
Q1 2020 -163 +74.2 +31.3% Mar 31, 2020
Q4 2019 -121* +163 Dec 31, 2019
Q3 2019 -122 +251 +67.4% Sep 30, 2019
Q2 2019 -131 Jun 30, 2019
Q1 2019 -237 Mar 31, 2019
Q4 2018 -284 Dec 31, 2018
Q3 2018 -373 Sep 30, 2018
Q3 2016 -282 Sep 30, 2016
Q2 2016 -428 Jun 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.